Cervical dilatation by sulprostone prior to vacuum aspiration for termination of early pregnancy.
In the period May 1983-October 1986 we treated 335 primigravidae requesting an abortion in the first trimester. They were given 500 micrograms sulprostone (16-phenoxy-omega-tetranor-PGE2-methylsulfonylamide) i.m. 12 to 14 hours before suction termination in order to obtain adequate and atraumatic cervical dilatation and thus reduce the possible risk of cervical incompetence and its consequences. The effects of this technique on the uterine cervix were compared with those obtained in 100 primigravidae after the insertion of laminaria to induce atraumatic cervical dilatation. We also evaluated the normal degree of cervical dilatation before any intervention in a control group of 100 primigravidae. The results obtained with sulprostone encourage the use of this drug to minimize cervical injury. The incidence of side-effects was not particularly high.
De Bonis
F
F
Istituto per l'Infanzia Trieste, Dèpartment of Obstetrics and Gynaecology, Trieste, Italy.
Santin
A M
AM
Mandruzzato
G P
GP
D000019:Abortifacient Agents / Q000009:adverse effects / Q000494:pharmacology*; D000028:Abortion, Induced; D000293:Adolescent; D000328:Adult; D002584:Cervix Uteri / Q000187:drug effects*; D004107:Dilatation and Curettage; D015232:Dinoprostone / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular; D007795:Laminaria; D011247:Pregnancy; D011261:Pregnancy Trimester, First; D014619:Vacuum Curettage
D000019:Abortifacient Agents; C016767:sulprostone; D015232:Dinoprostone